Sign In
Buy CHRS
$1.46
-0.0200 (-1.35%)
At Close: Jun 23, 2026
Coherus Biosciences (NASDAQ:CHRS) Upgraded at BidaskClub
09:04am, Monday, 27'th Apr 2020
BidaskClub upgraded shares of Coherus Biosciences (NASDAQ:CHRS) from a sell rating to a hold rating in a report published on Thursday, BidAskClub reports. CHRS has been the topic of a number of other
Coherus Biosciences Shows Market Leadership With Jump To 86 RS Rating
12:00am, Monday, 27'th Apr 2020Coherus Biosciences (NASDAQ:CHRS) Downgraded by Zacks Investment Research
09:28am, Sunday, 26'th Apr 2020
Zacks Investment Research downgraded shares of Coherus Biosciences (NASDAQ:CHRS) from a buy rating to a hold rating in a research note released on Wednesday morning, Zacks.com reports. According to Za
Bank of America Corp DE Reduces Position in Coherus Biosciences Inc (NASDAQ:CHRS)
08:38am, Sunday, 26'th Apr 2020
Bank of America Corp DE lessened its stake in shares of Coherus Biosciences Inc (NASDAQ:CHRS) by 29.1% during the 4th quarter, according to the company in its most recent filing with the Securities an
Lumos Pharma Hires Biotech Veteran Aaron Schuchart as Chief Business Officer
12:00pm, Friday, 24'th Apr 2020
Lumos Pharma, Inc. (LUMO), a clinical-stage biopharmaceutical company focused on therapeutics for rare diseases, announced that Aaron Schuchart will be joining the company as Chief Business Officer st
Coherus Biosciences Inc (NASDAQ:CHRS) Short Interest Down 5.4% in March
07:42am, Friday, 24'th Apr 2020
Coherus Biosciences Inc (NASDAQ:CHRS) saw a significant decline in short interest in March. As of March 31st, there was short interest totalling 10,990,000 shares, a decline of 5.4% from the March 15t
Gilead Sciences (GILD) Receives a Buy from Mizuho Securities
06:07pm, Thursday, 23'rd Apr 2020
Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences (GILD) today and set a price target of $81.00. The company's shares closed
Gilead Sciences (GILD) Receives a Buy from Mizuho Securities
06:07pm, Thursday, 23'rd Apr 2020
Mizuho Securities analyst Salim Syed maintained a Buy rating on Gilead Sciences (GILD – Research Report) today and set a
Coherus BioSciences to Report First Quarter Financial Results on May 7th
01:30pm, Wednesday, 22'nd Apr 2020
REDWOOD CITY, Calif., April 22, 2020 -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that its first quarter 2020 financial results will.
Coherus BioSciences to Report First Quarter Financial Results on May 7th
01:30pm, Wednesday, 22'nd Apr 2020
REDWOOD CITY, Calif., April 22, 2020 (GLOBE NEWSWIRE) -- Coherus BioSciences, Inc. (“Coherus” or the “Company”, Nasdaq: CHRS), today announced that its...
Analysts Offer Insights on Healthcare Companies: Biogen (BIIB) and Medtronic (MDT)
12:05pm, Wednesday, 22'nd Apr 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (BIIB) and Medtronic (MDT). Biogen (BIIB) Mizuho Securities
Analysts Offer Insights on Healthcare Companies: Biogen (NASDAQ: BIIB) and Medtronic (NYSE: MDT)
12:05pm, Wednesday, 22'nd Apr 2020
Analysts have been eager to weigh in on the Healthcare sector with new ratings on Biogen (
BIIB
–
Research Report
) and Medtronic (
MDT
–
Research Report
).
Biogen (BIIB)
Mizuho Securities analyst
Coherus Biosciences Inc (NASDAQ:CHRS) COO Vincent R. Anicetti Sells 5,150 Shares of Stock
10:14am, Wednesday, 22'nd Apr 2020
Coherus Biosciences Inc (NASDAQ:CHRS) COO Vincent R. Anicetti sold 5,150 shares of the company’s stock in a transaction that occurred on Monday, April 20th. The stock was sold at an average price of
Insider Selling: Coherus Biosciences Inc (NASDAQ:CHRS) COO Sells 5,000 Shares of Stock
09:40am, Wednesday, 22'nd Apr 2020
Coherus Biosciences Inc (NASDAQ:CHRS) COO Vincent R. Anicetti sold 5,000 shares of Coherus Biosciences stock in a transaction on Friday, April 17th. The stock was sold at an average price of $15.57, f
